Barrington Research Reiterates “Outperform” Rating for Option Care Health (NASDAQ:OPCH)

Option Care Health (NASDAQ:OPCH)‘s stock had its “outperform” rating restated by analysts at Barrington Research in a report released on Wednesday, Benzinga reports. They presently have a $38.00 target price on the stock. Barrington Research’s target price indicates a potential upside of 29.74% from the company’s previous close. Barrington Research also issued estimates for Option Care Health’s Q1 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.37 EPS and FY2026 earnings at $1.55 EPS.

Separately, Jefferies Financial Group upped their target price on Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, March 4th.

Option Care Health Price Performance

OPCH stock opened at $29.29 on Wednesday. The firm has a 50 day moving average of $32.04 and a 200-day moving average of $31.50. The company has a market cap of $5.09 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 1.65 and a beta of 1.22. The company has a current ratio of 1.77, a quick ratio of 1.33 and a debt-to-equity ratio of 0.74. Option Care Health has a 12-month low of $24.23 and a 12-month high of $35.74.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. The firm had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The firm’s revenue was up 12.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.21 EPS. As a group, equities analysts expect that Option Care Health will post 1.17 EPS for the current fiscal year.

Insider Buying and Selling

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of Option Care Health stock in a transaction on Monday, February 26th. The shares were bought at an average price of $31.55 per share, with a total value of $1,104,250.00. Following the purchase, the director now directly owns 269,528 shares in the company, valued at approximately $8,503,608.40. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.64% of the stock is owned by company insiders.

Institutional Trading of Option Care Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mutual of America Capital Management LLC boosted its position in shares of Option Care Health by 63.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 190,684 shares of the company’s stock worth $6,424,000 after acquiring an additional 73,938 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Option Care Health by 15.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,896,392 shares of the company’s stock valued at $93,698,000 after purchasing an additional 397,627 shares during the last quarter. HealthInvest Partners AB acquired a new position in shares of Option Care Health in the 4th quarter valued at $1,254,000. Ontario Teachers Pension Plan Board purchased a new stake in shares of Option Care Health during the 3rd quarter valued at $546,000. Finally, Van ECK Associates Corp increased its holdings in shares of Option Care Health by 244.2% during the 3rd quarter. Van ECK Associates Corp now owns 34,291 shares of the company’s stock worth $1,109,000 after buying an additional 24,328 shares during the last quarter. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.